Global Artificial Intelligence (AI) in Drug Discovery Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143114
- Pages: 225
-
Format:
Short Description
Global Artificial Intelligence (AI) in Drug Discovery Market, By Application (Novel Drug Candidates, Drug Optimization and Repurposing Preclinical Testing and Approval, Drug Monitoring, Finding New Diseases Associated Targets and Pathways, Understanding Disease Mechanisms, Aggregating and Synthesizing Information, Formation & Qualification of Hypotheses, De Novo Drug Design, Finding Drug Targets of an Old Drug, and Others), Technology (Machine Learning, Deep Learning, Natural Language Processing, and Others), Drug Type (Small Molecule and Large Molecule), Offering (Software and Services.), Indication (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, and Others), End Use (Contract Research Organizations (CRO), Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, New Zealand, Philippines, Indonesia, and Rest of Asia-Pacific, UAE, Israel, South Africa, Saudi Arabia, Egypt, and Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2029
Market Definition
Artificial Intelligence (AI) has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use. The first commercialized demonstrations of how AI (also known as Deep Learning (DL), Machine Learning (ML), or Artificial Neural Networks (ANNs)) could assist clinicians are now available. These systems could lead to a paradigm shift in clinician workflow, increase productivity while simultaneously enhancing treatment and patient throughput. AI for drug discovery is a technology that uses machines to simulate human intelligence to solve complicated challenges in the drug development procedure. The adoption of AI solutions in the clinical trial process eliminates possible obstacles, reduces clinical trial cycle time, and increases the productivity and accuracy of the clinical trial process. Therefore, the adoption of these advanced AI solutions in drug discovery processes is gaining popularity amongst life science industry stakeholders. In the pharmaceutical sector, it aids in the discovery of novel compounds, therapeutic target identification, and the development of customized medications. AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases.
Market Segmentation
The global Artificial Intelligence (AI) in drug discovery market is categorized into six notable segments: application, technology, drug type, offering, indication, and end use.
On the basis of application, the market is segmented into novel drug candidates, drug optimization and repurposing preclinical testing and approval, drug monitoring, finding new diseases associated targets and pathways, understanding disease mechanisms, aggregating and synthesizing information, formation & qualification of hypotheses, de novo drug design, finding drug targets of an old drug, and others
On the basis of technology, the market is segmented into Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and others
On the basis of drug type, the market is segmented into small molecule and large molecule
On the basis of offering, the market is segmented into software and services
On the basis of indication, the market is segmented into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others
On the basis of end use, the market is segmented into pharmaceutical & biotechnology companies, Contract Research Organizations (CROs), research centers and academic institutes, others
Market Players
The key market players operating in the global Artificial Intelligence (AI) in drug discovery market are listed below:
NVIDIA Corporation
IBM Corp.
Atomwise Inc.
Microsoft
Benevolent AI
Aria Pharmaceuticals, Inc.
DEEP GENOMICS
Exscientia
Cloud
Insilico Medicine
Cyclica
NuMedii, Inc.
Envisagenics
Owkin Inc.
BERG LLC
Schrdinger, Inc.
XtalPi Inc.
BIOAGE Inc.
TABLE OF CONTENTS
1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.3 OVERVIEW OF GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET 34
1.4 CURRENCY AND PRICING 36
1.5 LIMITATIONS 36
1.6 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 DBMR TRIPOD DATA VALIDATION MODEL 43
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.6 MULTIVARIATE MODELLING 47
2.7 MARKET APPLICATION COVERAGE GRID 48
2.8 SOURCE LIFELINE CURVE 49
2.9 DBMR MARKET POSITION GRID 50
2.10 VENDOR SHARE ANALYSIS 52
2.11 SECONDARY SOURCES 53
2.12 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHT 58
4.1 PESTEL ANALYSIS 60
4.2 PORETSRS FIVE FORCES 61
5 MARKET OVERVIEW 62
5.1 DRIVERS 64
5.1.1 THE RISE IN INCIDENCE OF CHRONIC DISEASES PROPELS NEED FOR ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY 64
5.1.2 STRATEGIC COLLABORATIONS, PARTNERSHIPS, AND PRODUCTS LAUNCH 64
5.1.3 REDUCTION IN TOTAL TIME INVOLVED IN DRUG DISCOVERY PROCESS 65
5.1.4 ADVANCEMENT OF ARTIFICIAL INTELLIGENCE IN THE HEALTHCARE INDUSTRY 65
5.2 RESTRAINTS 66
5.2.1 HIGH COST ASSOCIATED WITH TECHNOLOGY AND TECHNICAL LIMITATIONS 66
5.2.2 DISADVANTAGES AND RISKS ASSOCIATED WITH AI IN DRUG DISCOVERY 66
5.2.3 LACK OF AVAILABLE QUALITY DATA 66
5.3 OPPORTUNITIES 67
5.3.1 RISE IN THE INVESTMENTS FOR R&D 67
5.3.2 RISING HEALTHCARE INFRASTRUCTURE 67
5.3.3 DEVELOPMENT OF NOVEL TOOLS 68
5.4 CHALLENGES 68
5.4.1 THE GLOBAL SHORTAGE OF AI TALENT 68
5.4.2 ETHICAL, LEGAL, AND REGULATORY ISSUES FOR AI ADOPTION IN THE PHARMACEUTICAL SCIENCES 69
6 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING 70
6.1 OVERVIEW 71
6.2 SOFTWARE 74
6.2.1 INTEGRATED 75
6.2.2 STANDALONE 75
6.3 SERVICES 75
7 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 77
7.1 OVERVIEW 78
7.2 MACHINE LEARNING (ML) 81
7.2.1 SUPERVISED LEARNING 82
7.2.2 UNSUPERVISED LEARNING 82
7.2.3 REINFORCEMENT LEARNING 82
7.3 DEEP LEARNING 82
7.4 NATURAL LANGUAGE PROCESSING (NLP) 83
7.5 OTHERS 84
8 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY DRUG TYPE 85
8.1 OVERVIEW 86
8.2 SMALL MOLECULE 89
8.3 LARGE MOLECULE 89
9 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION 91
9.1 OVERVIEW 92
9.2 NOVEL DRUG CANDIDATES 95
9.2.1 PREDICT BIOACTIVITY OF SMALL MOLECULE 96
9.2.2 IDENTIFY BIOLOGICS TARGET 96
9.2.3 OTHERS 96
9.3 DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL 96
9.4 DRUG MONITORING 97
9.5 AGGREGATING AND SYNTHESIZING INFORMATION 98
9.6 DE NOVO DRUG DESIGN 98
9.7 FINDING DRUG TARGETS OF AN OLD DRUG 99
9.8 FORMATION & QUALIFICATION OF HYPOTHESES 100
9.9 UNDERSTANDING DISEASE MECHANISMS 101
9.10 FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS 101
9.11 OTHERS 102
10 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION 104
10.1 OVERVIEW 105
10.2 IMMUNE-ONCOLOGY 108
10.2.1 BREAST CANCER 109
10.2.2 LUNG CANCER 109
10.2.3 COLORECTAL CANCER 109
10.2.4 PROSTATE CANCER 109
10.2.5 PANCREATIC CANCER 109
10.2.6 BRAIN CANCER 109
10.2.7 LEUKEMIA 110
10.2.8 OTHERS 110
10.3 NEURODEGENERATIVE DISEASES 110
10.4 CARDIOVASCULAR DISEASES 111
10.5 METABOLIC DISEASES 111
10.6 OTHERS 112
11 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY END USE 113
11.1 OVERVIEW 114
11.2 CONTRACT RESEARCH ORGANIZATIONS 117
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 117
11.4 RESEARCH CENTERS AND ACADEMIC INSTITUTES 118
11.5 OTHERS 119
12 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION 120
12.1 OVERVIEW 121
12.2 NORTH AMERICA 126
12.2.1 U.S. 134
12.2.2 CANADA 138
12.2.3 MEXICO 142
12.3 EUROPE 146
12.3.1 U.K. 154
12.3.2 FRANCE 158
12.3.3 GERMANY 162
12.3.4 SPAIN 166
12.3.5 ITALY 170
12.3.6 RUSSIA 174
12.3.7 NETHERLANDS 178
12.3.8 SWITZERLAND 182
12.3.9 TURKEY 186
12.3.10 BELGIUM 190
12.3.11 REST OF EUROPE 194
12.4 ASIA-PACIFIC 195
12.4.1 CHINA 203
12.4.2 JAPAN 207
12.4.3 SOUTH KOREA 211
12.4.4 INDIA 215
12.4.5 AUSTRALIA & NEW ZEALAND 219
12.4.6 SINGAPORE 223
12.4.7 THAILAND 227
12.4.8 MALAYSIA 231
12.4.9 INDONESIA 235
12.4.10 PHILIPPINES 239
12.4.11 REST OF ASIA-PACIFIC 243
12.5 SOUTH AMERICA 244
12.5.1 BRAZIL 252
12.5.2 ARGENTINA 256
12.5.3 REST OF SOUTH AMERICA 260
12.6 MIDDLE EAST & AFRICA 261
12.6.1 SOUTH AFRICA 269
12.6.2 ISRAEL 273
12.6.3 SAUDI ARABIA 277
12.6.4 U.A.E 281
12.6.5 EGYPT 285
12.6.6 REST OF MIDDLE EAST AND AFRICA 289
13 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 290
13.1 COMPANY SHARE ANALYSIS: GLOBAL 290
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 291
13.3 COMPANY SHARE ANALYSIS: EUROPE 292
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 293
14 SWOT ANALYSIS 294
15 COMPANY PROFILES 295
15.1 NVIDIA CORPORATION 295
15.1.1 COMPANY SNAPSHOT 295
15.1.2 REVENUE ANALYSIS 295
15.1.3 COMPANY SHARE ANALYSIS 296
15.1.4 PRODUCT PORTFOLIO 296
15.1.5 RECENT DEVELOPMENTS 296
15.2 MICROSOFT 297
15.2.1 COMPANY SNAPSHOT 297
15.2.2 REVENUE ANALYSIS 297
15.2.3 COMPANY SHARE ANALYSIS 298
15.2.4 PRODUCT PORTFOLIO 298
15.2.5 RECENT DEVELOPMENT 298
15.3 IBM CORP 299
15.3.1 COMPANY SNAPSHOT 299
15.3.2 REVENUE ANALYSIS 299
15.3.3 COMPANY SHARE ANALYSIS 300
15.3.4 PRODUCT PORTFOLIO 300
15.3.5 RECENT DEVELOPMENT 300
15.4 SCHRDINGER, INC. 301
15.4.1 COMPANY SNAPSHOT 301
15.4.2 REVENUE ANALYSIS 301
15.4.3 COMPANY SHARE ANALYSIS 302
15.4.4 PRODUCT PORTFOLIO 302
15.4.5 RECENT DEVELOPMENTS 302
15.5 BERG LLC 304
15.5.1 COMPANY SNAPSHOT 304
15.5.2 COMPANY SHARE ANALYSIS 304
15.5.3 PRODUCT PORTFOLIO 304
15.5.4 RECENT DEVELOPMENTS 305
15.6 ARDIGEN 306
15.6.1 COMPANY SNAPSHOT 306
15.6.2 PRODUCT PORTFOLIO 306
15.6.3 RECENT DEVELOPMENTS 306
15.7 EXSCIENTIA 307
15.7.1 COMPANY SNAPSHOT 307
15.7.2 REVENUE ANALYSIS 307
15.7.3 PRODUCT PORTFOLIO 308
15.7.4 RECENT DEVELOPMENTS 308
15.8 ARIA PHARMACEUTICALS, INC. 309
15.8.1 COMPANY SNAPSHOT 309
15.8.2 PRODUCT PORTFOLIO 309
15.8.3 RECENT DEVELOPMENTS 309
15.9 ATOMWISE INC. 311
15.9.1 COMPANY SNAPSHOT 311
15.9.2 PRODUCT PORTFOLIO 311
15.9.3 RECENT DEVELOPMENTS 311
15.10 BENEVOLENT AI 313
15.10.1 COMPANY SNAPSHOT 313
15.10.2 REVENUE ANALYSIS 313
15.10.3 PRODUCT PORTFOLIO 314
15.10.4 RECENT DEVELOPMENTS 314
15.11 BIOAGE INC., 315
15.11.1 COMPANY SNAPSHOT 315
15.11.2 PRODUCT PORTFOLIO 315
15.11.3 RECENT DEVELOPMENTS 315
15.12 CLOUD 316
15.12.1 COMPANY SNAPSHOT 316
15.12.2 PRODUCT PORTFOLIO 316
15.12.3 RECENT DEVELOPMENT 316
15.13 CYCLICA 317
15.13.1 COMPANY SNAPSHOT 317
15.13.2 PRODUCT PORTFOLIO 317
15.13.3 RECENT DEVELOPMENTS 317
15.14 DEEP GENOMICS 319
15.14.1 COMPANY SNAPSHOT 319
15.14.2 PRODUCT PORTFOLIO 319
15.14.3 RECENT DEVELOPMENTS 319
15.15 ENVISAGENICS 321
15.15.1 COMPANY SNAPSHOT 321
15.15.2 PRODUCT PORTFOLIO 321
15.15.3 RECENT DEVELOPMENTS 321
15.16 INSILICO MEDICINE 323
15.16.1 COMPANY SNAPSHOT 323
15.16.2 PRODUCT PORTFOLIO 323
15.16.3 RECENT DEVELOPMENTS 323
15.17 NUMEDII, INC. 325
15.17.1 COMPANY SNAPSHOT 325
15.17.2 PRODUCT PORTFOLIO 325
15.17.3 RECENT DEVELOPMENT 325
15.18 OWKIN INC. 326
15.18.1 COMPANY SNAPSHOT 326
15.18.2 PRODUCT PORTFOLIO 326
15.18.3 RECENT DEVELOPMENT 326
15.19 XTALPI INC. 327
15.19.1 COMPANY SNAPSHOT 327
15.19.2 PRODUCT PORTFOLIO 327
15.19.3 RECENT DEVELOPMENTS 327
16 QUESTIONNAIRE 329
17 RELATED REPORTS 332
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
